Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tournis, Symeon
START, NCT06164795: Sequential Therapies After Osteoanabolic Treatment	Recruiting	N/A	150	Europe	Zoledronate, zoledronic acid; zolendronate, Denosumab, Dmab, Teriparatide, TPTD, Romosozumab, Romo	424 General Military Hospital	Osteoporosis, Postmenopausal	12/25	12/25
EURODEC, NCT05575167: Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)	Recruiting	N/A	125	Europe	Zoledronate or Alendronate, Calcium and vitamin D supplementation	424 General Military Hospital	Osteoporosis, Postmenopausal	11/26	11/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tournis, Symeon
START, NCT06164795: Sequential Therapies After Osteoanabolic Treatment	Recruiting	N/A	150	Europe	Zoledronate, zoledronic acid; zolendronate, Denosumab, Dmab, Teriparatide, TPTD, Romosozumab, Romo	424 General Military Hospital	Osteoporosis, Postmenopausal	12/25	12/25
EURODEC, NCT05575167: Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)	Recruiting	N/A	125	Europe	Zoledronate or Alendronate, Calcium and vitamin D supplementation	424 General Military Hospital	Osteoporosis, Postmenopausal	11/26	11/26